U.K. review of Upjohn's Halcion
Company representatives met with British regulatory officials Dec. 3 to appeal the U.K.'s Oct. 2 withdrawal of the benzodiazepine product, Upjohn Senior VP-Finance Robert Salisbury told Dec. 3 analysts meeting. Upjohn "expects to hear something within the next week as to their decision," Salisbury said, adding that the company anticipates an "uphill battle" to persuade British authorities to reverse their decision ("The Pink Sheet" Oct. 7, p. 11). On Dec. 11, Upjohn will meet with a Halcion review subcommittee of the European Community's Committee for Proprietary Medicinal Products that will develop recommendations for the full committee's consideration.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth